MGluR1 blockade might be a potential enhancer of GABA release [43,62], which could be responsible for the neuroprotective role reached by selective mGluR1 antagonists under various toxic conditions like ischemia [63,64] or in clinical environments for the treatment of anxiety, depression [65] or schizophrenia [42]. Here, GRM1 is linked to major depressive disorder.